These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9484869)

  • 41. Comparative in vitro activity of older and newer fluoroquinolones against respiratory tract pathogens.
    Esposito S; Noviello S; Ianniello F
    Chemotherapy; 2000; 46(5):309-14. PubMed ID: 10965095
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tentative interpretive criteria and quality control parameters for in-vitro susceptibility testing of Neisseria gonorrhoeae to two fluoroquinolones (PD 131628 and grepafloxacin (OPC 17116)).
    Sewell DL; Barry AL; Allen SD; Fuchs PC; Murray PR; Tenover FC
    J Antimicrob Chemother; 1996 Jan; 37(1):139-43. PubMed ID: 8647755
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
    Inoue M; Kuga A; Kaieda S; Hosaka M; Kitasato H; Sato Y; Okamoto R; Eda T; Hoshino K; Seto I
    Jpn J Antibiot; 2000 Sep; 53(9):593-608. PubMed ID: 11214999
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro susceptibility of anaerobes to quinolones in the United States.
    Hecht DW; Wexler HM
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S2-8. PubMed ID: 8953099
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
    Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Fluoroquinolones: pharmacology, antibacterial spectrum and indications in pneumology].
    Underner M; Grignon B; Roblot F; Meurice JC; Patte F
    Rev Pneumol Clin; 1989; 45(1):14-22. PubMed ID: 2662344
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of grepafloxacin.
    Efthymiopoulos C
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():35-43. PubMed ID: 9484872
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
    Choi KH; Hong JS; Kim SK; Lee DK; Yoon SJ; Choi EC
    J Antimicrob Chemother; 1997 Apr; 39(4):509-14. PubMed ID: 9145824
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [In vitro evaluation of lomefloxacin].
    Dette GA; Knothe H
    Arzneimittelforschung; 1989 Aug; 39(8):832-5. PubMed ID: 2818672
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The comparative arthropathy of fluoroquinolones in dogs.
    Takizawa T; Hashimoto K; Minami T; Yamashita S; Owen K
    Hum Exp Toxicol; 1999 Jun; 18(6):392-9. PubMed ID: 10413244
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [In vitro antibacterial activity of lomefloxacin, a new fluoroquinolone, against hospital strains. Results of a multicenter study].
    Soussy CJ; Le Van Thoi J; Morel C; Acar JF; Thabaut A; Fleurette J; Vallée E; Dabernat H; Chanal M; Drugeon H
    Pathol Biol (Paris); 1990 May; 38(5):390-6. PubMed ID: 2195448
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
    Croom KF; Goa KL
    Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phototoxicity in quinolones: comparison of ciprofloxacin and grepafloxacin.
    Ferguson J; Dawe R
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():93-8. PubMed ID: 9484878
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical toxicological aspects of fluoroquinolones.
    Stahlmann R
    Toxicol Lett; 2002 Feb; 127(1-3):269-77. PubMed ID: 12052667
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Grepafloxacin: microbiological properties.
    Marriott MS
    Clin Microbiol Infect; 1998 Mar; 4 Suppl 1():S9-S14. PubMed ID: 11869244
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systemic management of cutaneous bacterial infections.
    Parish LC; Witkowski JA
    Am J Med; 1991 Dec; 91(6A):106S-110S. PubMed ID: 1662878
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative uptake of grepafloxacin and ciprofloxacin by a human monocytic cell line, THP-1.
    Hara T; Takemura H; Kanemitsu K; Yamamoto H; Shimada J
    J Infect Chemother; 2000 Sep; 6(3):162-7. PubMed ID: 11810558
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics and efficacy of the new quinolones in infections of the eye, ear, nose, and throat.
    Barza M
    Rev Infect Dis; 1988; 10 Suppl 1():S241-7. PubMed ID: 3279497
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The serum concentrations of desmethyl ofloxacin and ofloxacin N-oxide in seriously ill patients and their possible contributions to the antibacterial activity of ofloxacin.
    Körner RJ; McMullin CM; Bowker KA; White LO; Reeves DS; MacGowan AP
    J Antimicrob Chemother; 1994 Aug; 34(2):300-3. PubMed ID: 7814297
    [No Abstract]   [Full Text] [Related]  

  • 60. Differential uptake of grepafloxacin by human circulating blood neutrophils and those exudated into tissues.
    Niwa M; Hotta K; Kanamori Y; Matsuno H; Kozawa O; Hirota M; Uematsu T
    Eur J Pharmacol; 2001 Sep; 428(1):121-6. PubMed ID: 11779028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.